



Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer

December 7, 2017

Evanston, Ill., Dec 7, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the appointment of Andy Kidd, B.M. B.Ch., as chief commercial officer to support the continued advancement of Aptinyx's robust pipeline of N-methyl-D-aspartate (NMDA) receptor modulating therapies in clinical development.

Andy's appointment aligns with Aptinyx's recent progress, including early- and mid-stage clinical studies of drug candidates NYX-783 and NYX-2925 in post-traumatic stress disorder and neuropathic pain, respectively. As Aptinyx continues to expand and advance its pipeline and build a multi-product biopharmaceutical company, Andy's experience will be instrumental in achieving and leveraging anticipated milestones, including progression of existing clinical programs into late-stage development, advancement of additional pipeline programs into the clinic, and delivery of novel and meaningful therapies to patients in need.

"We are thrilled to have an industry veteran of Andy's caliber join our executive team," said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. "This important addition will bolster our experience and commercial capabilities, which will help us fully realize the potential of our novel and diverse drug discovery platform and bring significant therapeutic improvements to patients suffering from various CNS disorders."

The addition of Mr. Kidd as Aptinyx's chief commercial officer brings to the company an entrepreneurial leader with more than 15 years of commercial, corporate, and business development experience in the life sciences. Prior to joining Aptinyx, Mr. Kidd served in various roles at Baxter International for over 10 years, most recently as senior vice president of strategy and business development. Prior, he held a number of commercial leadership positions, including general manager of Baxter Canada, global franchise head for surgical care, as well as general manager of the company's U.S. anesthesia and cardiovascular franchises. Before joining Baxter, Mr. Kidd worked as a pharmaceutical and healthcare consultant for The Boston Consulting Group in both London and Chicago. Mr. Kidd received his Bachelor of Medicine and Bachelor of Surgery degrees (B.M. B.Ch.) from the University of Oxford and a Bachelor of Arts in medical sciences from the University of Cambridge.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. Drugs that modulate NMDA receptors in this distinct way have both robust efficacy and exceptionally favorable safety. The company's lead drug candidate, NYX-2925, is in Phase 2 clinical development as a therapy for neuropathic pain and its second drug candidate, NYX-783, is in Phase 1 clinical development for the treatment of post-traumatic stress disorder (PTSD). Both programs have received Fast Track designation by the FDA. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.